We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
Did you mean Diabetes shakes?
How to use an interrupted time series to evaluate your digital health product.
You may need to tell DVLA if you have diabetes, depending on the treatment you're getting
Advice for medical professionals to follow when assessing drivers with diabetes mellitus.
Guidance on the safe and effective use of GLP-1 medicines for weight loss and diabetes.
How to use a cost effectiveness analysis to evaluate your digital health product.
The latest in a series of publications on diabetes by The Health and Social Care Information Centre. It covers the period 2005/06 to 2015/16.
Resources to help local commissioners achieve value for money by estimating the return on investment (ROI) and cost-effectiveness of public health programmes.
An overview of the NHS diabetic eye screening (DES) programme, its services and contact information.
As with any medicine, the MHRA will keep the safety and effectiveness of teplizumab under close review.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. Please fill in this survey (opens in a new tab and requires JavaScript).